Sign In
Buy AYTU
$2.09
-0.0100 (-0.476%)
At Close: Jun 03, 2026
Aytu BioScience, Inc. (AYTU) CEO Joshua Disbrow on Q2 2021 Results - Earnings Call Transcript
05:43am, Friday, 12'th Feb 2021
Aytu BioScience, Inc. (AYTU) CEO Joshua Disbrow on Q2 2021 Results - Earnings Call Transcript
Play Stocks With Rising P/E to Realize Solid Gains
07:36am, Monday, 08'th Feb 2021
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts
02:03pm, Thursday, 31'st Dec 2020
Long-term investors in Aytu BioScience have endured a series of value and confidence eroding actions by the company over the last 12 months including dilution and reverse splits. Aytu has significant
Why These 4 Health Care Stocks Are Moving Today
02:10pm, Monday, 28'th Dec 2020
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scler
Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients
08:05am, Monday, 28'th Dec 2020
First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients ENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 / Aytu BioScie
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos Therapeutics, Inc.
07:35pm, Thursday, 10'th Dec 2020
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the propose
Merger Thursday: Gilead Buys German Drug Company, Aytu-Neos All-Stock Deal, Boehringer Picks Up NBE-Therapeutics
11:00am, Thursday, 10'th Dec 2020
The day dawned as an M&A Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. (NASDAQ: GILD) and Aytu BioScience, Inc. (NASDAQ: AYTU) in the
Neos Therapeutics News: Why NEOS Stock Is Soaring Today
10:46am, Thursday, 10'th Dec 2020
Neos Therapeutics (NEOS) news for Thursday concerning a merger with Aytu BioScience (AYTU) has shares of NEOS and AYTU stock on the rise. The post Neos Therapeutics News: Why NEOS Stock Is Soaring Tod
Where Do Hedge Funds Stand On Aytu BioScience, Inc. (AYTU)?
06:33pm, Thursday, 26'th Nov 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filing
Aytu BioScience Announces Launch of Nationwide Mobile COVID-19 Testing Initiative
12:00pm, Wednesday, 19'th Aug 2020
Aytu BioScience COVID-19 IgG/IgM Rapid Test Distribution Partner Apollo Med Innovations Initiates Nationwide Mobile Testing Partnership with Olympus Health and PerformanceENGLEWOOD, CO / ACCESSWIRE /
Is Aytu BioScience (NASDAQ:AYTU) Using Debt In A Risky Way?
03:35pm, Monday, 17'th Aug 2020
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study
12:00pm, Monday, 17'th Aug 2020
Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 PatientsENGLEWOOD, CO / ACCESSWIRE / Aug
Acerus Pharmaceuticals Corporation (ASPCF) CEO Ed Gudaitis on Q2 2020 Results - Earnings Call Transcript
05:50pm, Tuesday, 11'th Aug 2020
Acerus Pharmaceuticals Corporation (OTCQB:ASPCF) Q2 2020 Earnings Conference Call August 11, 2020, 10:00 AM ET Company Participants Bob Motz - CFO Ed Gudaitis - President and CEO Conference Call Parti
Acerus Reports Fiscal 2020 Second Quarter Financial Results
12:00am, Tuesday, 11'th Aug 2020
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month
Cancer Targeted Technology receives $1.44M in year 2 of SBIR Phase IIB grant to fund clinical trial of new PSMA-targeted therapeutic agent, CTT1403.
